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Abstract 
Background: The Tridax procumbens flavonoids (TPF), are well known for their medicinal properties among local 
natives. The TPF are traditionally used for dropsy, anaemia, arthritis, gout, asthma, ulcer, piles, and urinary problems. 
It also used in treating gastric problems, body pain, and rheumatic pains of joints. The TPF have been reported to 
increase osteogenic functioning in mesenchymal stem cells. However, their effects on osteoclastogenesis remain 
unclear. The TPF isolated from T. procumbens and investigated the effects of the TPF inhibit on osteoclast differentia‑
tion and bone resorption activities using primary osteoclastic cells. Osteoclast formation was assessed by counting 
the number of tartrate resistant acid phosphatase (TRAP) positive multinucleated cells and by measuring both TRAP 
activities.
Results: The TPF significantly suppressed the RANKL‑induced differentiation of osteoclasts and the formation of pits 
in primary osteoclastic cells. The TPF also decreased the expression of mRNAs related to osteoclast differentiation, 
including Trap, Cathepsin K, Mmp‑9, and Mmp‑13 in primary osteoclastic cells. The treatment of primary osteoclastic 
cells with the TPF decreased Cathepsin K, Mmp‑9, and Mmp‑13 proteins expression in primary osteoclastic cells.
Conclusion: These results indicated that TPF inhibit osteoclastogenesis and pits formation activities. Our results sug‑
gest that the TPF could be a potential anti‑bone resorptic agent to treat patients with bone loss‑associated diseases 
such as osteoporosis.
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Background
The human bone is a highly dynamic organ that main-
tains its homeostasis through a delicate balance between 
the bone-forming osteoblasts and the bone-eroding oste-
oclasts [1, 2]. The dynamic balance between these two 
cells types results in bone remodeling. Osteoclasts are 
multinucleated giant cells that differentiated from cells 
of hematopoietic monocyte macrophage linage under 
the presence of two critical factors: the receptor activator 
of NF-kB ligand (RANKL) and the macrophage mono-
cyte colony-stimulating factor (M-CSF) [2]. Both factors 
are produced by osteoblasts or stromal cells [2]. Osteo-
clasts, which are essential in bone homeostasis, play a 
key role in the development of osteoporosis, inflamma-
tory arthritis, and rheumatoid arthritis (RA), osteoporo-
sis, or low bone mineral density (BMD), is a important 
risk factor for fracture in older women [3]. Progressive 
bone destruction in RA involves the abnormal activation 
of osteoclasts, which is due to interactions with synovial 
fibroblasts and helper T cells that express the RANKL [4, 
5]. Traditional medicine is an important source of poten-
tially useful new compounds for the development of 
therapeutic agents [6]. Emergence of pathogenic micro-
organisms that are resistant or multi-resistant to major 
class of antibiotics has increased in recent years due to 
indiscriminate use of synthetic antimicrobial drugs [7]. In 
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addition, high cost and adverse side effects are commonly 
associated with popular synthetic antibiotics such as 
hypersensitivity, allergic reactions, immunosuppression 
and are major burning global issues in treating diseases 
[8]. Hence, recent attention has been paid to biologically 
active extracts and compounds from plant species used in 
herbal medicines [9]. It has been proved effective in the 
treatment of diseases simultaneously mitigating many of 
the side effects which are often associated with synthetic 
antibiotics [10]. Positive response of plant based drugs 
and less or no side effects might lies in the structure of the 
natural products which reacts with toxins and/or patho-
gens in such a way that less harm is done to other impor-
tant molecules or physiology of host. The flavonoids 
isolated from Tridax procumbens (TPF) were selected 
in the present study for evaluation of their anti-bone 
resorptive activities. The T. procumbens is well adapted 
to the harsh climatic conditions and is well known for 
their medicinal properties among local natives. Whole 
plants is made into paste and applied on fresh cuts [11]. 
In ayurvedic medicine, the TPF is recorded as a hepatic 
stimulant. The TPF from leaves and root bark are tradi-
tionally used for dropsy, anaemia, arthritis, and gout. It is 
used for the treatment of asthma, ulcer, piles, and urinary 
problems [12]. The TPF is also used in treating gastric 
problems, body pain, and rheumatic pains of joints [13, 
14], however, no data were found regarding the pharma-
cological and phytochemical evaluation. The aim of the 
study was to clarify the TPF inhibits on osteoclasts dif-
ferentiation and bone resorption activities using primary 
osteoclastic cells. In this study, osteoclast formation was 
assessed by counting the number of tartrate resistant acid 
phosphatase (TRAP) positive multinucleated cells and by 
measuring both TRAP activities. Present results demon-
strated that the TPF inhibited osteoclasts differentiation 
and TRAP activities.
Results
Effect of the TPF on osteoclast formation
To examine the effect of the TPF on osteoclast forma-
tion, cultures of the primary osteoclast cells were treated 
with the TPF at concentrations of 0, 50 and 100 μg/ml 
for 7 days. Greater numbers of TRAP-positive multinu-
cleated osteoclasts were observed in the control group 
in comparison with the TPF treated groups (Fig. 1a, c). 
Osteoclasts treated with 50 and 100  μg/ml of the TPF 
were smaller and exhibited fewer nuclei than osteo-
clasts of the control group (Fig. 1a, c). Moreover, treat-
ment with 100  μg/ml of the TPF resulted in markedly 
fewer multinucleated osteoclasts in cultures to com-
pare in the control group. Treatment with 100  μg/ml 
of the TPF strongly suppressed cell–cell fusion among 
the primary osteoclast cells (Fig. 1a). The TPF inhibited 
mature osteoclasts in terms of formation of TRAP-pos-
itive multinuclear osteoclasts (Fig.  1a–d). TRAP-posi-
tive multinucleated osteoclasts activity and osteoclast 
surface area were decreased significantly in cultures 
treated with 50 and 100 μg/ml of the TPF than the con-
trol group. Treatment with the TPF reduced the num-
ber of mature osteoclasts were dose dependent manner 
(Fig. 1a).
The TPF inhibited pit formation
The TPF inhibited RANKL-induced pit formation and 
dose dependently reduced pit formation in the primary 
osteoclast cells at concentrations of 50 and 100 μg/ml of 
the TPF compare to the control group (Fig.  2a–c). The 
TPF inhibited mature osteoclasts formation and resorp-
tion pit were decreased significantly in cultures treated 
with 50 and 100 μg/ml of the TPF than the control group. 
Treatment with the TPF reduced the total resorpted area 
of mature osteoclasts (Fig. 1a–c).
Effect of the TPF on mRNA expression level in the primary 
osteoclast cells
Following treatment with the TPF for 7 days, all cells in 
each well were harvested; subsequently, cells were used 
to reverse transcribe mRNA directly into cDNA with the 
Whole Transcriptase Amplification Kit. The Trap, Cath-
epsin K, Mmp-9 and Mmp-13 mRNA levels per well were 
significantly lower in the TPF-treated cells than in control 
cells (Fig. 3b–e). Moreover, the Trap, Cathepsin K, Mmp-
9 and Mmp-13 mRNA levels were substantially lower in 
cells treated with 100  μg/ml of the TPF in comparison 
with cells treated with 50 μg/ml of the TPF affected The 
Trap, Cathepsin K, Mmp-9 and Mmp-13 mRNA levels in 
a dose dependent manner (Fig. 3b–e).
Effect of the TPF on Cathepsin K, MMP‑9 and MMP‑13 
activity
The primary osteoclast cells culture supernatant samples 
obtained after 7  days in cultures. The pro-Cathepsin K, 
pro-MMP-9 and pro-MMP-13 activity was detected in 
all samples (Fig.  4a–d). The Cathepsin K, MMP-9 and 
MMP-13 samples were diluted with ddH2O prior to 
measurement of enzymatic activity. Pro-Cathepsin K, 
pro-MMP-9 and pro-MMP-13 activity were significantly 
lower in those samples derived from cultures treated with 
50 and 100 μg/ml of the TPF than in the samples derived 
from control cultures (Fig.  4a–d). Moreover, The TPF 
reduced pro-Cathepsin K, pro-MMP-9 and pro-MMP-13 
activity in a dose dependent manner (Fig. 4a–d). The con-
centration of 100 μg/ml of the TPF appeared to suppress 
pro-Cathepsin K, pro-MMP-9 and pro-MMP-13 activity 
to a greater extent than the concentration of 50 μg/ml of 
the TPF.
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Discussion
The present study found that the TPF at doses between 50 
and 100  μg/ml significantly inhibited RANKL-induced 
differentiation of osteoclasts in the primary osteoclastic 
cells. In doses up to 100 μg/ml of the TPF was not toxic 
to cultured osteoclast cells (data not shown). It had an 
inhibitory effect on osteoclasts differentiation of primary 
osteoclast cells (Figs.  1a–d, 2a–c). Traditional medicines 
play an important role in health services around the globe. 
The rational design of novel drugs from traditional medi-
cine offers new prospects in modern healthcare [6, 7, 15]. 
Dietary habits are known to play a role in the prevention 
of osteoporosis. Some studies investigated that the poten-
tial benefits of fruits, vegetables, tea, and herbs on bone 
metabolism [15, 16]. It was showed that the consumption 
of vegetables and fruits inhibited bone resorption in rats 
better than meat or milk [17]. The meat and milk products 
commonly believed to be beneficial for bone health [17]. In 
South Asia, including Bangladesh, India, Pakistan, Nepal 
and Srilanka, the TPF is made into paste and applied on 
fresh cuts [11]. Decoctions of the TPF from T. procumbens 
leaves and root bark have been traditionally used for treat-
ment of dropsy, anaemia, arthritis, and gout, ulcer, piles, and 
urinary problems [12]. The TPF also used in the treatment 
for fever, typhoid, cough, and diarrhea, gastric problems, 
body pain, and rheumatic pains of joints [18–20]. TPF has 
antimicrobial effects such as antibacterial, antifungal and 
antiviral [21–23]. Recently, our study showed that the TPF 
can promote the osteoblasts differentiation and bone for-
mation (data submitted). This study investigated the direct 
effects of the TPF on RANKL-induced osteoclastogenesis in 
the primary osteoclast cells. The primary osteoclast cells do 
not contain any osteoblast or bone marrow stromal cells or 
cytokines [24–26]. The TPF blocked the function of osteo-
clasts and inhibited osteoclastogenesis and TRAP activity. 
This inhibition occurred at the stage of osteoclastogenesis 
when cell fusion and multinucleated cell formation occurs. 
However, we did not find cytotoxic or cell cycle arrest in the 
primary osteoclast cells when treated with the TPF at con-
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Fig. 1 Effect of the TPF on osteoclast formation in vitro. Cells were cultured with RANKL (30 ng/ml) and M‑CSF (30 ng/ml) for 7 days in the presence 
of 0, 50 or 100 μg/ml of the TPF. Osteoclasts were identified via tartrate‑resistant acid phosphatase (TRAP). a TRAP+ cells are shown in red and the 
magnification in a represent ×10, b TRAP+ multinucleated cells characterized by more than three nuclei were counted, c osteoclast number/well 
(N.Oc/well), d osteoclast surface/well (Oc.S/well). The data were expressed as the mean ± SD (n = 4) for each group. *p < 0.05
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Based on the results, the TPF probably blocked osteoclas-
togenesis by preventing RANKL-mediated activity.
Conclusion
In summary, this study found that the TPF dose depend-
ently suppressed the osteoclast differentiation in cultured 
primary osteoclast cells. The regulation of osteoclast dif-
ferentiation might be an important strategy for the treat-
ment of bone resorption and osteoporosis. The current 
study demonstrated that the TPF suppress differentiation 
in primary osteoclast cells. Our results revealed that the 




Tridax procumbens plant was identified and authen-
ticated by Professor Dr. Anwarul Islam, Department 
pharmacy, Rajshahi University, Bangladesh. Samples 
were collected from the northeast part of Bangladesh and 
stored at the Plant Biotechnology laboratory, Depart-
ment of Genetic Engineering and Biotechnology, Shah-
jalal University of Science and Technology, Sylhet-3114, 
Bangladesh (Serial no. GEB09032014/3). Different parts 
of T. procumbens (root, stem, leaf, and flowers) were 
separately shade dried, finely powdered using a blender, 
and subjected to extraction following the method as 
described elsewhere, with some modifications [27, 28].
Reagents
Penicillin, streptomycin, α-MEM, and fetal bovine serum 
were purchased from Invitrogen (Carlsbad, CA, USA). 
Recombinant soluble human M-CSF, human RANKL, 
Recombinant soluble human M-CSF and human RANKL 
and all other reagents were purchased from Sigma-
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Fig. 2 Effect of the TPF on osteoclast activity as indicated by resorption pit area. Cells were cultured with RANKL (30 ng/ml) and M‑CSF (30 ng/ml) 
for 7 days in the presence of 0, 50 or 100 μg/ml of the TPF and discs were fixed and stained with toluidine blue. a Effects of the TPF on the bone 
resorbing activity mature osteoclasts and the magnification in a represent ×10, b total resorbed pit area/well and c resorbed pit area/osteoclasts. 
The data were expressed as the mean ± SD (n = 4) for each group. *p < 0.05
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Animals
C57BL/6 male mice were obtained from ICDDRB 
(Dhaka, Bangladesh) and maintained in our animal care 
facilities as described elsewhere [29, 30]. The experimen-
tal procedures were reviewed and approved by the Ani-
mal Care and Use Committee of Shahjalal University of 
Science and Technology, Sylhet, Bangladesh.
Osteoclast formation
For the primary osteoclast cells, 8  weeks old female 
C57BL/6 mice were killed by CO2 asphyxia, then the 
femur and tibia bones were dissected aseptically. The 
marrow cells were flushed out with α-minimum essen-
tial medium (α-MEM, Carlsbad, CA, USA). Bone 
marrow cells (1.5  ×  104  cells/well) were cultured in 
α-MEM containing 50  ng/ml  M-CSF and 50  ng/ml 
RANKL. The cells were assigned to three groups as 
follows 0, 50, and 100  μg/ml the TPF. Media were 
changed on the fourth day. The TPF was added to the 
appropriate cultures each of the 5 days. After incuba-
tion, the cells underwent TRAP staining using a Tar-
trate Resistant Acid Phosphatase Kit. We observed 
the TRAP-positive multinucleated cells (with three 
or more nuclei) under light microscopy and counted 
them using image analyzing system (KS400; Carl Zeiss, 
Jena, Germany).
TRAP activity measurement
After five  days culture of bone marrow-derived oste-
oclasts with appropriate treatment were lysed and 
incubated for 1 h with a reaction buffer containing para-
nitrophenylphosphate (pNPP). The reaction was stopped 
with 0.3  N NaOH solutions, and optical densities were 
read and analyzed by microplate spectrophotometer at 
405 nm (T60 U, PG Instruments Ltd., England).
Osteoblasts and osteoclasts co‑culture
Eight weeks old female C57BL/6 mice were killed by 
CO2 asphyxia, then the femur and tibia bones were dis-
sected aseptically.   The marrow cells were flushed out 
with α-minimum essential medium. The bones (without 
marrow) were cut into pieces (less than 1 mm in diam-
eter), digested with 0.2 % collagenase for 1 h to harvest 
the mature osteoblast cells. For the osteoclast co-culture 
cells model, the cells were seeded into 6-wells plates at a 
density of osteoblasts 2 × 105 cells and bone marrow cells 
Fig. 3 Effect of the TPF on mRNA expression in primary osteoclast cells. a TRAP+ cells are shown in red and the magnification in a represent ×10, 
b relative mRNA of Trap expression level, c relative mRNA of Cathepsin K expression level, d relative mRNA of Mmp‑9 expression level and relative 
mRNA of Mmp‑13 expression level. The data were expressed as the mean ± SD (n = 4) for each group. *p < 0.05
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1.4 × 107 cells/well in α-MEM supplemented with 10 % 
fetal bovine serum, antibiotics (100 U/ml of penicillin 
G and streptomycin 100 ng/ml) in a humidified atmos-
phere with 5 % CO2 and 95 % air at 37 °C. The cells were 
assigned to three groups as follows 0, 50, and 100 mg/
ml the TPF. Media were changed on the fourth day. The 
TPF was added to the appropriate cultures each of the 5 
days.  After incubation, the cells underwent TRAP stain-
ing using a Tartrate Resistant Acid Phosphatase Kit. 
We observed the TRAP-positive multinucleated cells 
(with three or more nuclei) under light microscopy and 
counted them using image analyzing system (KS400; Carl 
Zeiss, Jena, Germany).
Functional bone resorption assay
The primary osteoclast cells were cultured with RANKL 
(50  ng/ml) and M-CSF (50  ng/ml) for 21  days. Vari-
ous concentrations of the TPF were added to cultured 
media to measure osteoclastic cell-mediated mineral 
resorption. After the culture period, cells were removed 
using 6  % NaOCl and 5.2  % NaCl. The resorption area 
was observed under a light microscope and analyzed by 
using image analyzing system (KS400; Carl Zeiss, Jena, 
Germany).
Reverse transcriptase‑polymerase chain reaction analysis
Osteoclasts cells were seeded in 6-well plates for 7 days at 
37 °C in 5 % CO2 in an osteoclast differentiation medium 
containing 50  ng/ml M-CSF and 50  ng/ml RANKL at a 
density of 1 × 106 cells/well and cells were treated with 
the TPF at concentrations of 0, 50, and 100 μg/ml. Total 
RNA from the cells of each well was isolated using Nucle-
oSpin (Macherey–Nagel, Duren, Germany). RNA ali-
quots were reverse transcribed to complementary DNAs 
by using an oligo (dT) primer (Roche), deoxynucleotide 
triphosphate (dNTP), and Moloney murine leukemia 
virus (M-MuLV) reverse transcriptase (Fermentas, Han-
over, MD, USA). The complementary DNA products 
were subjected to PCR amplification with gene-specific 
primers for mouse Cathepsin K, Mmp-9, and Mmp-13 
(Table  1). Real-time RT-PCR amplification was per-
formed using a Light Cycler System (Roche) with a Plati-
num SYBR Green qPCR Super Mix UDG kit (Invitrogen, 
Carlsbad, CA, USA).
Fig. 4 Effects of the TPF on Cathepsin K, MMP‑9, MMP‑13 and β‑actin expression in primary osteoclast cells. a The TPF down regulated Cathepsin K, 
MMP‑9 and MMP‑13 proteins expression and β‑actin served as the control for the protein assay, b cathepsin K activity, c MMP‑9 activity and d MMP‑
13 activity. The data were expressed as the mean ± SD (n = 4) for each group. *p < 0.05
Page 7 of 7Al Mamun et al. Biol Res  (2015) 48:51 
Statistical analysis
We used analysis of variance with an F-test, followed by a 
t-test. P values less than 0.05 were considered significant. 
The data are presented as mean ± standard deviation val-
ues of independent replicates.
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Cathepsin K 5′CGAAAAGAGCCTAGCGA 3′TGGGTAGCAGCAGAAACA
MM9 5′GAACCAATCTCACCGA 
CAGG
3′GCCACCCGAGTGTAACCATA
MM13 5′GTCTGAGATTTGTAGG 
CCG
3′TCATCAAGCTTCTGTCT 
GTGC
